AUSTIN, Texas– Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) secreted from bone marrow-derived mesenchymal stem cells (BM-MSCs) to address multiple disease indications, announces favorable safety data and significant efficacy results from its Phase 2 clinical trial (NCT04493242) of ExoFlo™ in hospitalized adult COVID-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). [Read more…]

The company’s MEV universal delivery system has the potential to overcome biological barriers in the body and solve current drug delivery challenges.

Paris, April 3, 2023 – AGS Therapeutics, an early-stage biotech company pioneering micro-algae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, today announced its initial internal research and development (R&D) pipeline. It is designed to showcase the potential of its MEVs as a new groundbreaking delivery system for bringing a wide range of payloads, including mRNA, siRNA, plasmid-DNA, antisense oligonucleotides (ASO), peptides, and proteins, to a variety of tissues and organs for treatment of a wide range of diseases. MEVs can overcome many of the challenges met by current delivery systems based on mammalian extracellular vesicles and on synthetic lipid nanoparticles. [Read more…]

Collaboration with La Trobe University, The University of Queensland, Australian National University, Cytiva and SeerPharma Pty Ltd

19 January 2023, Melbourne, Australia – VivaZome Therapeutics Pty Ltd (“VivaZome”) is delighted to announce that it has been awarded an Australian Government Round 13 CRC-P grant of $3.0m in support of the project “Customised exosomes – the future of regenerative medicine”. [Read more…]